Abstract:Anxiety disorders are prevalent and disabling yet understudied from a genetic standpoint, compared with other major psychiatric disorders such as bipolar disorder and schizophrenia. The fact that they are more common, diverse and perceived as embedded in normal life may explain this relative oversight. In addition, as for other psychiatric disorders, there are technical challenges related to the identification and validation of candidate genes and peripheral biomarkers. Human studies, particularly genetic ones, are susceptible to the issue of being underpowered, because of genetic heterogeneity, the effect of variable environmental exposure on gene expression, and difficulty of accrual of large, well phenotyped cohorts. Animal model gene expression studies, in a genetically homogeneous and experimentally tractable setting, can avoid artifacts and provide sensitivity of detection. Subsequent translational integration of the animal model datasets with human genetic and gene expression datasets can ensure cross-validatory power and specificity for illness. We have used a pharmacogenomic mouse model (involving treatments with an anxiogenic drug—yohimbine, and an anti-anxiety drug—diazepam) as a discovery engine for identification of anxiety candidate genes as well as potential blood biomarkers. Gene expression changes in key brain regions for anxiety (prefrontal cortex, amygdala and hippocampus) and blood were analyzed using a convergent functional genomics (CFG) approach, which integrates our new data with published human and animal model data, as a translational strategy of cross-matching and prioritizing findings. Our work identifies top candidate genes (such as FOS, GABBR1, NR4A2, DRD1, ADORA2A, QKI, RGS2, PTGDS, HSPA1B, DYNLL2, CCKBR and DBP), brain–blood biomarkers (such as FOS, QKI and HSPA1B), pathways (such as cAMP signaling) and mechanisms for anxiety disorders—notably signal transduction and reactivity to environment, with a prominent role for the hippocampus. Overall, this work complements our previous similar work (on bipolar mood disorders and schizophrenia) conducted over the last decade. It concludes our programmatic first pass mapping of the genomic landscape of the triad of major psychiatric disorder domains using CFG, and permitted us to uncover the significant genetic overlap between anxiety and these other major psychiatric disorders, notably the under-appreciated overlap with schizophrenia. PDE10A, TAC1 and other genes uncovered by our work provide a molecular basis for the frequently observed clinical co-morbidity and interdependence between anxiety and other major psychiatric disorders, and suggest schizo-anxiety as a possible new nosological domain.

Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis

Polygenicity of Comorbid Depression in Multiple Sclerosis

Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling

Meta-analyses of genome-wide linkage scans of anxiety-related phenotypes

Identification of novel genomic loci for anxiety symptoms and extensive genetic overlap with psychiatric disorders

Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study

Comorbidity alters the genetic relationship between anxiety disorders and major depression

Heritability and polygenic load for combined anxiety and depression

Gene Discovery and Biological Insights into Anxiety Disorders from a Multi-Ancestry Genome-wide Association Study of >1.2 Million Participants

Comorbid-phenome prediction and phenotype risk scores enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder

The Prevalence and Risk Factors of Anxiety in Multiple Sclerosis: A Systematic Review and Meta-Analysis

Genetic liability for anxiety associates with treatment response to the monoamine stabilizer OSU6162 in alcohol dependence

Analysis of common genetic variation of anxiety disorders in essential tremor

Genetics of psycho-emotional well-being: genome-wide association study and polygenic risk score analysis

Identification of Novel Rare Variants for Anxiety: an Exome-Wide Association Study in the UK Biobank

Unraveling COVID-19 relationship with anxiety disorders and symptoms using genome-wide data

Polygenic Liability to Depression Is Associated With Multiple Medical Conditions in the Electronic Health Record: Phenome-wide Association Study of 46,782 Individuals

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms

Association of Anxiety with Uncinate Fasciculus Lesion Burden in Multiple Sclerosis

Neuroticism as a Common Factor in Depression and Anxiety Associated with Multiple Sclerosis—A Systematic Review and Meta-Analysis

Symptom-level modelling unravels the shared genetic architecture of anxiety and depression